دورية أكاديمية
أعرض في EDS

Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer.

التفاصيل البيبلوغرافية
العنوان: Exploratory comparisons between different anti-mitotics in clinically-used drug combination in triple negative breast cancer.
المؤلفون: Guido BC; Microscopy and Microanalysis Laboratory, Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil., Brandão DC; Microscopy and Microanalysis Laboratory, Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil., Barbosa ALA; Microscopy and Microanalysis Laboratory, Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil., Vianna MJX; Microscopy and Microanalysis Laboratory, Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil., Faro L; Microscopy and Microanalysis Laboratory, Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil., Ramos LM; Laboratory of Medicinal Chemistry and Organic Syntesis, Exact and Technological Sciences Campus, State University of Goiás, Anápolis, Goiás 75001-970, Brazil., Nihi F; Microscopy and Microanalysis Laboratory, Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil., de Castro MB; Veterinary Pathology Laboratory, Faculty of Agronomy and Veterinary Medicine, Department of Veterinary Medicine, University of Brasília, Brasília 70910-970, Brazil., Neto BAD; Laboratory of Medicinal and Technological Chemistry, University of Brasília, Chemistry Institute, University of Brasília, Brasília 70904-900, Brazil., Corrêa JR; Microscopy and Microanalysis Laboratory, Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil., Báo SN; Microscopy and Microanalysis Laboratory, Department of Cell Biology, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil.
المصدر: Oncotarget [Oncotarget] 2021 Sep 14; Vol. 12 (19), pp. 1920-1936. Date of Electronic Publication: 2021 Sep 14 (Print Publication: 2021).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Albany, N.Y. : Impact Journals
مستخلص: Triple-negative breast cancer (TNBC) constitutes a very aggressive type of breast cancer with few options of cytotoxic chemotherapy available for them. A chemotherapy regimen comprising of doxorubicin hydrochloride and cyclophosphamide, followed by paclitaxel, known as AC-T, is approved for usage as an adjuvant treatment for this type of breast cancer. In this study we aimed to elucidate the role of KIF11 in TNBC progression throughout its inhibition by two synthetic small molecules containing the DHPM core (dihydropyrimidin-2(1H)-ones or -thiones), with the hypothesis that these inhibitors could be an interesting option of antimitotic drug used alone or as adjuvant therapy in association with AC. For this purpose, we evaluated the efficacy of DHPMs used as monotherapy or in combination with doxorubicin and cyclophosphamide, in Balbc-nude mice bearing breast cancer induced by MDA-MB-231, having AC-T as positive control. Our data provide extensive evidence to demonstrate that KIF11 inhibitors showed pronounced antitumor activity, acting in key points of tumorigenesis and cancer progression in in vivo xenograft model of triple negative breast cancer, like down-regulation of KIF11 and ALDH1-A1. Moreover, they didn't show the classic peripheral neuropathy characterized by impaired mobility, as it is common with paclitaxel use. These results suggest that the use of a MAP inhibitor in breast cancer regimen treatment could be a promising strategy to keep antitumoral activity reducing the side effects.
Competing Interests: CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
(Copyright: © 2021 Guido et al.)
التعليقات: Erratum in: Oncotarget. 2022 Sep 28;13:1068. (PMID: 36187557)
References: Exp Cell Res. 2000 Jun 15;257(2):231-7. (PMID: 10837136)
Pathology. 2016 Apr;48(3):214-8. (PMID: 27020495)
BMC Cancer. 2015 Apr 14;15:283. (PMID: 25885813)
J Breast Cancer. 2019 Nov 07;22(4):522-532. (PMID: 31897327)
Oncogene. 2018 Feb 15;37(7):833-838. (PMID: 29059174)
Chemistry. 2013 Mar 25;19(13):4156-68. (PMID: 23460474)
Blood. 1990 May 15;75(10):1947-50. (PMID: 2337669)
Cancer. 2012 Jul 15;118(14):3556-64. (PMID: 22139909)
Cancer Cell Int. 2013 Jun 15;13(1):60. (PMID: 23767668)
Med Oncol. 2011 Sep;28(3):745-52. (PMID: 20405247)
Medicine (Baltimore). 2016 Aug;95(35):e4614. (PMID: 27583878)
Biochem Pharmacol. 1999 Apr 1;57(7):727-41. (PMID: 10075079)
Med Oncol. 2013 Mar;30(1):476. (PMID: 23371254)
Future Med Chem. 2016;8(4):463-89. (PMID: 26976726)
Lung Cancer. 2017 Jun;108:168-172. (PMID: 28625631)
Mol Biol Cell. 2014 Sep 15;25(18):2677-81. (PMID: 25213191)
Proc Natl Acad Sci U S A. 1980 Mar;77(3):1561-5. (PMID: 6103535)
Int J Urol. 2011 Jun;18(6):432-8. (PMID: 21449971)
Anticancer Drugs. 2012 Mar;23(3):335-41. (PMID: 22123335)
J Neurooncol. 2016 Jan;126(1):77-80. (PMID: 26456023)
Cancer Chemother Pharmacol. 2017 Feb;79(2):315-326. (PMID: 28097385)
Drug Saf. 2000 Nov;23(5):401-28. (PMID: 11085347)
Cancer Res. 2017 May 15;77(10):2722-2734. (PMID: 28283655)
Cancer Res. 1992 Apr 1;52(7):1770-4. (PMID: 1551107)
Cell Stem Cell. 2007 Nov;1(5):555-67. (PMID: 18371393)
Oncotarget. 2017 Sep 8;8(54):92106-92118. (PMID: 29190901)
Front Cell Dev Biol. 2019 Dec 20;7:335. (PMID: 31921847)
Cell. 2018 May 3;173(4):879-893.e13. (PMID: 29681456)
Oncotarget. 2017 Jul 10;8(37):62208-62216. (PMID: 28977938)
Oncotarget. 2017 Jun 27;8(26):42510-42524. (PMID: 28489567)
Pharmacol Res. 2020 Mar;153:104683. (PMID: 32050092)
Clin Cancer Res. 2010 Jan 15;16(2):566-76. (PMID: 20068098)
Cancer Res. 2009 May 1;69(9):3901-9. (PMID: 19351824)
Histopathology. 2020 Sep;77(3):437-448. (PMID: 32369651)
N Engl J Med. 2010 Nov 11;363(20):1938-48. (PMID: 21067385)
J Med Chem. 2013 Aug 22;56(16):6317-29. (PMID: 23875972)
Anticancer Res. 2017 Jan;37(1):47-55. (PMID: 28011472)
J Cell Biol. 1996 Oct;135(2):399-414. (PMID: 8896597)
Cancer Res. 2009 Feb 15;69(4):1302-13. (PMID: 19190339)
Sci Transl Med. 2015 Sep 9;7(304):304ra143. (PMID: 26355032)
Dis Markers. 2017;2017:2176460. (PMID: 28684886)
Breast Cancer Res Treat. 2016 Apr;156(2):261-9. (PMID: 26975188)
Curr Biol. 2012 Nov 20;22(22):R966-80. (PMID: 23174302)
Cancer Res. 2007 Nov 1;67(21):10138-47. (PMID: 17974955)
Cancer Res. 2004 May 1;64(9):3276-80. (PMID: 15126370)
Invest New Drugs. 2016 Aug;34(4):399-406. (PMID: 26994617)
Oncotarget. 2013 Dec;4(12):2302-16. (PMID: 24327603)
Nouv Rev Fr Hematol. 1994;36 Suppl 1:S25-8. (PMID: 7909941)
Biochem Pharmacol. 2008 Jul 15;76(2):169-78. (PMID: 18539263)
Clin Cancer Res. 2010 Jan 1;16(1):45-55. (PMID: 20028757)
Nature. 1992 Oct 8;359(6395):540-3. (PMID: 1406972)
Invest New Drugs. 2008 Jun;26(3):265-72. (PMID: 18196204)
Oncology (Williston Park). 2008 Oct;22(11):1233-9; discussion 1239-40, 1243. (PMID: 18980022)
Cancer Sci. 2013 Jun;104(6):651-6. (PMID: 23438337)
J Natl Cancer Inst Monogr. 1993;(15):107-15. (PMID: 7912516)
Neoplasma. 2014;61(3):352-62. (PMID: 24824938)
Anticancer Res. 2018 Jun;38(6):3393-3400. (PMID: 29848688)
Breast Cancer Res. 2016 Jul 02;18(1):73. (PMID: 27368476)
Clin Cancer Res. 2012 Jan 1;18(1):51-63. (PMID: 22215906)
J Clin Oncol. 2008 Mar 10;26(8):1275-81. (PMID: 18250347)
فهرسة مساهمة: Keywords: KIF11 inhibition; Kinesin Eg5; adjuvant treatment; breast cancer; cancer progression
تواريخ الأحداث: Date Created: 20210922 Latest Revision: 20221003
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC8448514
DOI: 10.18632/oncotarget.28068
PMID: 34548908
قاعدة البيانات: MEDLINE
الوصف
تدمد:1949-2553
DOI:10.18632/oncotarget.28068